| DAA1981 |
Selective increase in oxidative damage and decrease in antioxidant function during aging in the substantia nigra |
Physiological |
substantia nigra |
Human |
— |
— |
|
| DAA219 |
selenium binding protein 1 |
Molecular |
brain |
Human |
SELENBP1 |
7.0% Increase Gene Expression Level |
|
| DAA222 |
selenophosphate synthetase 1 |
Molecular |
brain |
Human |
SEPHS1 |
12.0% Increase Gene Expression Level |
|
| DAA220 |
sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A |
Molecular |
brain |
Human |
SEMA6A |
8.0% Increase Gene Expression Level |
|
| DAA1273 |
seminal vesicle secretory protein 4 |
Molecular |
brain |
Mouse |
Svs4 |
2642.0% Increase Gene Expression Level |
|
| DAA743 |
Sensitivity of HPA axis is impaired |
Physiological |
pituitary gland, adrenal gland, hypothalamus |
Human |
— |
— |
|
| DAA229 |
serine peptidase inhibitor, Kunitz type, 2 |
Molecular |
brain |
Human |
SPINT2 |
3.0% Decrease Gene Expression Level |
|
| DAA223 |
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member |
Molecular |
brain |
Human |
SERPINF1 |
7.0% Decrease Gene Expression Level |
|
| DAA1436 |
serum/glucocorticoid regulated kinase 1 |
Molecular |
hippocampus |
Mouse |
Sgk1 |
9.0% Increase Gene Expression Level |
|
| DAA216 |
seryl-tRNA synthetase |
Molecular |
brain |
Human |
SARS |
10.0% Decrease Gene Expression Level |
|
| DAA217 |
sodium channel, voltage-gated, type II, beta |
Molecular |
brain |
Human |
SCN2B |
50.0% Decrease Gene Expression Level |
|
| DAA225 |
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
Molecular |
brain |
Human |
SLC17A7 |
9.0% Decrease Gene Expression Level |
|
| DAA1272 |
solute carrier family 17 (sodium phosphate), member 3 |
Molecular |
brain |
Mouse |
Slc17a3 |
11.0% Increase Gene Expression Level |
|
| DAA226 |
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
Molecular |
brain |
Human |
SLC25A4 |
9.0% Decrease Gene Expression Level |
|
| DAA1437 |
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5 |
Molecular |
hippocampus |
Mouse |
Slc25a5 |
2.0% Decrease Gene Expression Level |
|
| DAA1438 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
Molecular |
hippocampus |
Mouse |
Slc2a1 |
6.0% Increase Gene Expression Level |
|
| DAA166 |
solute carrier family 2 (facilitated glucose transporter), member 3 pseudogene 1 |
Molecular |
brain |
Human |
SLC2A3P1 |
17.0% Decrease Gene Expression Level |
|
| DAA228 |
sorting nexin 3 |
Molecular |
brain |
Human |
SNX3 |
5.0% Decrease Gene Expression Level |
|
| DAA766 |
Speech production problems |
Psychological |
brain |
Human |
— |
— |
|
| DAA224 |
S-phase kinase-associated protein 1 |
Molecular |
brain |
Human |
SKP1 |
4.0% Decrease Gene Expression Level |
|
| DAA67 |
sphingosine-1-phosphate receptor 1 |
Molecular |
brain |
Human |
S1PR1 |
27.0% Increase Gene Expression Level |
|
| DAA1435 |
splicing factor, arginine/serine-rich 5 (SRp40, HRS) |
Molecular |
hippocampus |
Mouse |
Sfrs5 |
3.0% Increase Gene Expression Level |
|
| DAA230 |
spondin 1, extracellular matrix protein |
Molecular |
brain |
Human |
SPON1 |
21.0% Increase Gene Expression Level |
|
| DAA231 |
stathmin-like 2 |
Molecular |
brain |
Human |
STMN2 |
6.0% Decrease Gene Expression Level |
|
| DAA627 |
Stroke |
Pathological |
brain |
Human |
— |
SeriesMorbidity |
|